<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305704</url>
  </required_header>
  <id_info>
    <org_study_id>STUD-192207</org_study_id>
    <nct_id>NCT04305704</nct_id>
  </id_info>
  <brief_title>Coated Mongolian Aneurysm Treatment Study 2</brief_title>
  <acronym>COMATS 2</acronym>
  <official_title>Clinical Evaluation of the p64 MW HPC and the p48 MW HPC Flow Diverters in an Observational Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenox GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenox GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW&#xD;
      HPC Flow Modulation Device under prasugrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Observational Registry With p64 MW HPC in Unruptured Anterior Circulation Aneurysms&#xD;
      Under prasugrel&#xD;
&#xD;
      Purpose: To assess safety and effectiveness of p64 MW HPC or p48 MW HPC under prasugrel in&#xD;
      consecutive patients with unruptured anterior circulation aneurysms.&#xD;
&#xD;
      Follow-up intervals: Independent follow-ups (after 3 to 6 months and after 12 months and&#xD;
      after 24 months) according to site specific standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>Within 30 days after the intervention</time_frame>
    <description>Occurence of ischemic or hemorrhagic stroke. Incidence of ischemic or hemorrhagic stroke in the territory supplied by the treated artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>Within the first 12 months after the intervention</time_frame>
    <description>Occurence of all adverse events and serious adverse events, related directly or indirectly to the intervention, the used device or the required medication.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy endpoint</measure>
    <time_frame>12 months after the intervention</time_frame>
    <description>Complete occlusion or the neck remnant of the target aneurysm(s), identified by DSA (Digital subtraction angiography).</description>
  </other_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Aneurysm</condition>
  <condition>Vascular Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for this Observational Registry are patients with unruptured&#xD;
        intracranial aneurysms suitable for flow diversion on operators' discretion. All patients&#xD;
        are tested for the extend of their platelet function inhibition prior treatment using&#xD;
        VerifyNow (a point-of-care test).&#xD;
&#xD;
        Patients can be included in the Observational Registry if they meet all of the inclusion&#xD;
        and none of the exclusion criteria and have provided written informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one unruptured sidewall aneurysm in the anterior circulation&#xD;
&#xD;
          -  No implant (e.g., stent) in the target vessel segment&#xD;
&#xD;
          -  Age &gt;18 years and &lt;80 years&#xD;
&#xD;
          -  Not pregnant and in women of childbearing age, on oral contraception for two years&#xD;
             following the procedure&#xD;
&#xD;
          -  No participation in another trial&#xD;
&#xD;
          -  No concomitant disease limiting the life expectancy to &lt;2 years&#xD;
&#xD;
          -  No allergy to non-ionic contrast medium or to ASA and P2Y12 receptor antagonists&#xD;
&#xD;
          -  No other neurovascular disorder in the same vascular territory requiring treatment in&#xD;
             the foreseeable future&#xD;
&#xD;
          -  Ability and willingness to comply with the medication requirements within the study,&#xD;
&#xD;
          -  Ability to understand the goal and risks of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracranial aneurysm considered not suitable for FD using p64 MW HPC or p48 MW HPC.&#xD;
&#xD;
          -  Aneurysm previously treated with a device in the parent vessel (e.g., stent, flow&#xD;
             diverter).&#xD;
&#xD;
          -  Another intracranial procedure scheduled for the following 6 months.&#xD;
&#xD;
          -  Age &lt; 18 years and &gt; 80 years.&#xD;
&#xD;
          -  Pregnancy possible or confirmed. Patient not able or willing to arrange contraception&#xD;
             for 12 months after treatment.&#xD;
&#xD;
          -  Patient not able or willing to adhere to the study protocol.&#xD;
&#xD;
          -  Patient not able or willing to undergo the scheduled follow-up examinations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Henkes, Prof. Dr.</last_name>
    <phone>+49 711 27834501</phone>
    <email>h.henkes@klinikum-stuttgart.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrey Petrov, Dr.</last_name>
    <email>doctorpetrovandrey@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shastin Central Hospital</name>
      <address>
        <city>Ulaanbaatar</city>
        <state>Bayangol District</state>
        <zip>10th khoroolol-2</zip>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganbaatar Rentsenkhuu, Dr.</last_name>
      <email>ganbaatar.neuro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ganbaatar Rentsenkhuu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p64 MW HPC</keyword>
  <keyword>p48 MW HPC</keyword>
  <keyword>Flow Diverter</keyword>
  <keyword>HPC</keyword>
  <keyword>Outcome</keyword>
  <keyword>Occlusion</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

